118 related articles for article (PubMed ID: 12698880)
1. Angiogenic switch as a molecular target of malignant tumors.
Tanaka S; Sugimachi K; Yamashita Y; Shirabe K; Shimada M; Wands JR; Sugimachi K
J Gastroenterol; 2003 Mar; 38 Suppl 15():93-7. PubMed ID: 12698880
[TBL] [Abstract][Full Text] [Related]
2. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma.
Tanaka S; Sugimachi K; Yamashita Yi Y; Ohga T; Shirabe K; Shimada M; Wands JR; Sugimachi K
Hepatology; 2002 Apr; 35(4):861-7. PubMed ID: 11915032
[TBL] [Abstract][Full Text] [Related]
3. Biological effect of ectopic expression of angiopoietin-1 and -2 in hepatocellular carcinoma cell line.
Peng L; Sun J; Wang WD; Jian ZX; Ou JR
Hepatobiliary Pancreat Dis Int; 2003 Feb; 2(1):94-7. PubMed ID: 14607656
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.
Mitsuhashi N; Shimizu H; Ohtsuka M; Wakabayashi Y; Ito H; Kimura F; Yoshidome H; Kato A; Nukui Y; Miyazaki M
Hepatology; 2003 May; 37(5):1105-13. PubMed ID: 12717391
[TBL] [Abstract][Full Text] [Related]
5. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis.
Taura K; De Minicis S; Seki E; Hatano E; Iwaisako K; Osterreicher CH; Kodama Y; Miura K; Ikai I; Uemoto S; Brenner DA
Gastroenterology; 2008 Nov; 135(5):1729-38. PubMed ID: 18823985
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
Wada H; Nagano H; Yamamoto H; Yang Y; Kondo M; Ota H; Nakamura M; Yoshioka S; Kato H; Damdinsuren B; Tang D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Sakon M; Dono K; Wakasa K; Monden M
Liver Int; 2006 May; 26(4):414-23. PubMed ID: 16629644
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
8. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch.
Zhang N; Zhong R; Perez-Pinera P; Herradon G; Ezquerra L; Wang ZY; Deuel TF
Biochem Biophys Res Commun; 2006 May; 343(2):653-8. PubMed ID: 16554021
[TBL] [Abstract][Full Text] [Related]
9. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
[TBL] [Abstract][Full Text] [Related]
10. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
11. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
Sarraf-Yazdi S; Mi J; Moeller BJ; Niu X; White RR; Kontos CD; Sullenger BA; Dewhirst MW; Clary BM
J Surg Res; 2008 May; 146(1):16-23. PubMed ID: 17950331
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice.
Lee K; Yun ST; Kim YG; Yoon Y; Jo EC
Hepatology; 2006 May; 43(5):1063-73. PubMed ID: 16628632
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
17. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.
Tanaka S; Mori M; Sakamoto Y; Makuuchi M; Sugimachi K; Wands JR
J Clin Invest; 1999 Feb; 103(3):341-5. PubMed ID: 9927494
[TBL] [Abstract][Full Text] [Related]
18. Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes.
Kunz P; Hoffend J; Altmann A; Dimitrakopoulou-Strauss A; Koczan D; Eisenhut M; Bonaterra GA; Dengler TJ; Mier W; Haberkorn U; Kinscherf R
J Nucl Med; 2006 Sep; 47(9):1515-24. PubMed ID: 16954561
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.
Almog N; Ma L; Raychowdhury R; Schwager C; Erber R; Short S; Hlatky L; Vajkoczy P; Huber PE; Folkman J; Abdollahi A
Cancer Res; 2009 Feb; 69(3):836-44. PubMed ID: 19176381
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
